AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19.
Flushed with the success of its COVID-19 vaccine, BioNTech has pressed the accelerator on the development of shots for other infectious diseases, and now plans to take malaria and tuberculo
GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm's prospects at an investor meeting last week would deflect criticism of her leadershi
Reports are emerging that the UK may join other countries in imposing restrictions on the use of AstraZeneca's COVID-19 vaccine in younger people, after a fresh look at the risks and benefi
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.